SecBot SecBot

NBIX

NEUROCRINE BIOSCIENCES INC
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0000914475 Biotech & Drug Discovery
$165.31 −2.09 (−1.25%)
Nov 16 4:00 PM ET · prev $167.40
Market cap
$17.1B
Large cap
Consensus
Buy
86% Buy or better · 37 analysts
Median target
🔒 Subscribers only
1 year
+15.2%
from $143.56 · Nov 17
30 days
+20.7%
from $136.98
52-week range
$123.10–185.50
−11% from high · low Feb 12
Avg volume 20D
1.46M
Nov 3 spike 4.06M
Short interest
5.90M
≈5.8% of shares · −8.5%
Days to cover
5.4
at average volume
Insider net
−$4.2M
0 buyers · 6 sellers · since Jul 10
New fund stakes
4
Q3 2026 13F · 2 exits
Filing reports
30
analyzed by SecBot
SecBot read BULLISH 14 reports · 90 days
Balance 0 bearish · 3 bullish · 1 mixed · 10 neutral oldest → newest, height = score
Avg score ·High conf. 10/14

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    6 insiders sold $4.2M.

  • InstitutionsBULLISH

    Q3 2026: 55 added (4 new), 32 trimmed or exited. Largest new: Jupiter Asset Management $35.7M.

  • AnalystsBULLISH

    32 of 37 rate it Buy or better.

  • Short sellersSTEADY

    Short interest −8.5% to 5.90M shares. 5.4 days to cover, ≈5.8% of shares.

  • TrendUPTREND

    11% above its 50-day average.

Who's buying

13F· Q3 2026
4
new positions
2
exits
$35.7M
in new stakes · top 1 shown
FundMoveSharesValue
VICTORY CAPITAL MANAGEMENT INCADD837,106$118.7M
Aberdeen Group plcDOUBLED1,183,444$112.8M
Ninety One UK LtdDOUBLED434,881$61.7M
BARCLAYS PLCADD412,021$58.4M
Candriam S.C.A.ADD344,883$49.1M
Zurcher Kantonalbank (Zurich Cantonalbank)DOUBLED342,638$48.6M
CITIGROUP INCADD294,376$41.8M
JUPITER ASSET MANAGEMENT LTDNEW252,030$35.7M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

37 analysts
Buy 86% rate it Buy or better
Strong Buy15Buy17Hold5Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Nov 13, 2026Morgan Stanley
MAINTAIN
MAINTAINEqual-Weight
Nov 4, 2026Guggenheim
MAINTAIN
MAINTAINBuy
Nov 3, 2026Morgan Stanley
MAINTAIN
MAINTAINEqual-Weight
Nov 3, 2026RBC Capital
MAINTAIN
MAINTAINOutperform
Nov 3, 2026Canaccord Genuity
MAINTAIN
MAINTAINBuy
Nov 3, 2026Piper Sandler
MAINTAIN
MAINTAINOverweight

Insider ledger

Form 4
$0
bought · 0 insiders
$4.2M
sold · 6 insiders
DateInsiderTypeValue
Nov 4, 2026
ROBERTS EIRY
Chief Medical Officer
Nov 4, 2026
AWARD8,314 sh
Nov 4, 2026
ROBERTS EIRY
Chief Medical Officer
Nov 4, 2026
AWARD1,506 sh
Nov 3, 2026
MORROW GEORGE J
Director
Nov 3, 2026
EXERCISE$386.2K
Nov 3, 2026
MORROW GEORGE J
Director
Nov 3, 2026
SELL$15.8K
Nov 3, 2026
MORROW GEORGE J
Director
Nov 3, 2026
SELL$16.2K
Nov 3, 2026
MORROW GEORGE J
Director
Nov 3, 2026
SELL$98.2K
Nov 3, 2026
MORROW GEORGE J
Director
Nov 3, 2026
SELL$202.0K
Nov 3, 2026
MORROW GEORGE J
Director
Nov 3, 2026
SELL$150.5K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Washington

Corporate Lobbying

41 lobbying filings and 6 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 30, 2026
5,900,825
shares short
-8.5%
vs prior settlement
5.4
days to cover
≈5.8%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 10, 2026 SEC
Sanjay Keswani, a former affiliate of Neurocrine Biosciences, filed a Form 144 notice of intent to sell 53,614 shares…
144 · Impact 2/10
Nov 10, 2026 Other
Neurocrine Biosciences to Present at the 2026 Jefferies Global Healthcare Conference
SAN DIEGO, Nov. 10, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today
Nov 10, 2026 SEC
The PTAB granted institution of post-grant review (PGR2026-00061) on Neurocrine's petition challenging claims of…
PTAB-TRIAL · Impact 3/10
Nov 10, 2026 SEC
The PTAB granted institution of post-grant review (PGR2026-00059) on Neurocrine's petition challenging Spruce…
PTAB-TRIAL · Impact 3/10
Nov 4, 2026 Insider
ROBERTS EIRY was granted 8,314 shares
Chief Medical Officer
Nov 4, 2026 Insider
ROBERTS EIRY was granted 1,506 shares
Chief Medical Officer
Nov 3, 2026 Insider
MORROW GEORGE J acquired via exercise 7,200 shares
Director @ $53.64 ($386.2K)
Oct 23, 2026 Event
INGREZZA
Supplemental Approval · Labeling · VALBENAZINE · CAPSULE · ORAL
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
9 drugs tracked · Drug pipeline →
Recent
Nov 13, 2026
Clinical Trial
Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEE
Phase 2 · TERMINATED
Nov 10, 2026
Press release
Neurocrine Biosciences to Present at the 2026 Jefferies Global Healthcare Conference
SAN DIEGO, Nov. 10, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that its executives will participate at the…
Nov 10, 2026
Ptab trial
PTAB PGR2026-00060: Trial instituted, U.S. Patent 12569490 (Spruce Biosciences, Inc. v. Neurocrine Biosciences, Inc.)
Patent: METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORS
Nov 10, 2026
Ptab trial
PTAB PGR2026-00059: Trial instituted, U.S. Patent 12569491 (Spruce Biosciences, Inc. v. Neurocrine Biosciences, Inc.)
Patent: METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORS
Nov 10, 2026
Ptab trial
PTAB PGR2026-00061: Trial instituted, U.S. Patent 12576084 (Spruce Biosciences, Inc. v. Neurocrine Biosciences, Inc.)
Patent: METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORS

SecBot reports

30 filings · 5 bullish · 1 bearish · 1 mixed · 23 neutral
All NBIX filing & press-release reports (30)